Andrew Dalovisio, MD
Hematology & Oncology · Baton Rouge, LANPI 1144458704
Payments from drug & device makers
Across 251 payments — averaging $1548.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$132K
- Johnson & Johnson$78K
- Pfizer$54K
- F. Hoffmann-la Roche AG$34K
- AstraZeneca$28K
- Agios Pharmaceuticals, Inc.$23K
- plus $39K from 31 others
Across 19 payments — averaging $728.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
- Novartis$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 16 | $132,487 |
| Johnson & Johnson | 74 | $77,936 |
| Pfizer | 12 | $54,279 |
| F. Hoffmann-la Roche AG | 6 | $34,250 |
| AstraZeneca | 32 | $27,826 |
| Agios Pharmaceuticals, Inc. | 9 | $22,944 |
| Genentech, Inc. | 1 | $19,500 |
| Genmab U.S., Inc. | 10 | $6,051 |
| Janssen Scientific Affairs, LLC | 11 | $5,416 |
| Janssen Global Services, LLC | 1 | $2,503 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Beigene USA, Inc. | 2 | $704 |
| Karyopharm Therapeutics Inc. | 5 | $703 |
| GSK | 6 | $533 |
| Novartis | 6 | $326 |
| Daiichi Sankyo Inc. | 8 | $256 |
| Adaptive Biotechnologies Corporation | 4 | $192 |
| AbbVie | 8 | $161 |
| Incyte Corporation | 1 | $99 |
| Bristol Myers Squibb | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $85 |
| Beone Medicines USA, Inc. | 4 | $73 |
| Merck | 3 | $69 |
| Sanofi | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Stemline Therapeutics Inc. | 2 | $43 |
| Bayer | 2 | $38 |
| Sobi, Inc | 2 | $37 |
| Gilead | 2 | $36 |
| Amgen | 1 | $30 |
| Array Biopharma Inc | 2 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Syndax Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
How this compares
$388,651 in reported general payments places this provider in the 85th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$3.8M
- Nakhle SabaBaton Rouge$2.4M
- Victor LinBaton Rouge$2.3M
- Marshall StaggBaton Rouge$1.6M
- William VarnadoBaton Rouge$648K
- Sobia OzairBaton Rouge$378K
- Sanjay JunejaBaton Rouge$346K
- Derrick SpellBaton Rouge$128K
- Christopher McCanlessBaton Rouge$80K
- Harry Sequeira GrossBaton Rouge$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.